Stoke Therapeutics Inc [STOK] stock is trading at $11.66, down -0.34%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The STOK shares have gain 2.64% over the last week, with a monthly amount glided 19.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on December 20, 2024, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $24. On March 26, 2024, upgrade upgraded it’s rating to Outperform. TD Cowen downgraded its rating to a Market Perform. BofA Securities upgraded its rating to Neutral for this stock on May 01, 2023, and upped its price target to $12.
Stoke Therapeutics Inc [STOK] stock has fluctuated between $5.35 and $16.62 over the past year. Currently, Wall Street analysts expect the stock to reach $30.6 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $11.66 at the most recent close of the market. An investor can expect a potential return of 162.44% based on the average STOK price forecast.
Analyzing the STOK fundamentals
Stoke Therapeutics Inc [NASDAQ:STOK] reported sales of 190.91M for the trailing twelve months, which represents a growth of 3661.12%. Gross Profit Margin for this corporation currently stands at 0.15% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.19 and Total Capital is 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.46 points at the first support level, and at 11.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.91, and for the 2nd resistance point, it is at 12.15.
Ratios To Look Out For
For context, Stoke Therapeutics Inc’s Current Ratio is 8.41. In addition, the Quick Ratio stands at 8.41 and the Cash Ratio stands at 6.15. Considering the valuation of this stock, the price to sales ratio is 3.33, the price to book ratio is 1.82 and price to earnings (TTM) ratio is 14.82.
Transactions by insiders
Recent insider trading involved Skorpios Trust, 10% Owner, that happened on Jun 04 ’25 when 3.0 million shares were sold. CHIEF MEDICAL OFFICER, Ticho Barry completed a deal on Jun 03 ’25 to sell 6471.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Ticho Barry sold 1745.0 shares on Jun 02 ’25.
